New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 13, 2012
08:31 EDTMDVNMedivation, Astellas XTANDI available to those previously treated with Docetaxel
Medivation and Astellas Pharma announced the availability of XTANDI capsules for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI was approved by the U.S. FDA on Aug. 31, 2012. XTANDI is being distributed through a network of specialty pharmacies and specialty distributors.
News For MDVN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
08:46 EDTMDVNMedivation price target raised to $128 from $107 at Leerink
Leerink raised its price target for Medivation shares to $128 after the company presented Stage 1 and preliminary Stage 2 data from the Phase II trial of Xtandi in advanced androgen receptor positive triple negative breast cancer. The firm believes the data demonstrate "clear single agent activity with confirmed objective responses" and keeps an Outperform rating on the stock.
December 12, 2014
18:05 EDTMDVNMedivation, Astellas Pharma report data from Phase 2 study of enzalutamide
Subscribe for More Information
December 9, 2014
08:48 EDTMDVNMedivation management to meet with Leerink
Subscribe for More Information
07:44 EDTMDVNAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use